10 unknown, 5 completed, 4 not yet recruiting, 1 active not recruiting. 16 Phase 2, 14 Phase 3, 3 Not applicable, 1 Phase 1.
Follow Busulfan (BU): new trials by email Literature Review of Busulfan (BU) trials Research Report on Busulfan (BU)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 26DT052; Scaling Busulfan Dose to Body Surface Area in Children Busulfan (BU) - Busulfan Pharmacokinetic Analysis, Busulfan Dosing | Phase 1 | Not yet recruiting | Children's Hospital of Philadelphia | 38 | 2026-09-01 | 2026-08-28 |
| A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients Venetoclax, Azacitidine (AZA), Decitabine 20 mg/m²/day for 5 days - Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-08-01 | 2026-08-19 |
| TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission Thiotepa, Busulfan (BU), Fludarabine - Acute Myeloid Leukemia | Not applicable | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 93 | 2026-06-01 | 2026-05-04 |
| Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) Venetoclax, None-placebo, Busulfan (BU) - Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 138 | 2025-08-20 | 2026-09-02 |
| VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT Venetoclax (VEN), Decitabine (DAC), Busulfan (Bu) - Older Patients, Myeloid Malignancies | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 160 | 2025-07-15 | 2025-07-04 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 232 | 2022-07-01 | 2022-07-08 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2022-07-01 | 2023-03-21 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2021-01-15 | 2021-01-19 |
| Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - TP53, Myeloid Tumors | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 196 | 2019-10-01 | 2019-10-10 |
| Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 196 | 2019-09-01 | 2019-09-23 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 20 | 2018-11-01 | 2018-11-07 |
| Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Allogeneic Hematopoietic Stem Cell Transplantation, Conditions | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2018-07-01 | 2018-07-24 |
| Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT Decitabine, Busulfan (BU), Fludarabine(Flu) - Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 60 | 2018-06-15 | 2020-12-22 |
| Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2018-01-02 | 2020-02-25 |
| BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2017-07-05 | 2017-10-12 |
| G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Decitabine, Busulfan (BU), Cyclophosphamide (CY) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 202 | 2016-04-18 | 2022-02-14 |
| IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT Idarubicin（IDA）, Busulfan (BU), Cyclophosphamide (CY) - Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 153 | 2016-01-01 | 2020-03-03 |
| BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT Busulfan (BU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan | Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 550 | 2016-01-01 | 2022-04-08 |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, fludarabine phosphate, busulfan - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | University of Wisconsin, Madison | 20 | 2013-05-16 | 2019-11-21 |
Showing 20 of 21. Sign in to see all of them.
Leukemia, Myeloid, Acute (7) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1) · Anemia, Sickle Cell (1) · Burkitt Lymphoma (1) · Congenital Abnormalities (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Disease (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemolysis (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Nanfang Hospital, Southern Medical University (14) · Children's Hospital of Philadelphia (1) · Emory University (1) · First Affiliated Hospital of Zhejiang University (1) · Masonic Cancer Center, University of Minnesota (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · The First Affiliated Hospital of Soochow University (1) · University of Wisconsin, Madison (1)
China (15) · United States (4)
Qifa Liu (12) · Lakshmanan Krishnamurti, MD (1) · Mark Juckett (1) · Xianmin Song (1) · Yanmin Zhao, MD (1)
PMID 32683127, PMID 36084276, PMID 36588387, PMID 36702138, PMID 40831735
P30CA014520 (1), R34HL108761 (1)